Cancer Immunology, Immunotherapy

Aims & Scope

Cancer Immunology, Immunotherapy has the basic aim of keeping readers informed of the latest research results in the fields of oncology and immunology.

As knowledge expands, the scope of the journal has broadened to include more of the progress being made in the areas of biology concerned with biological response modifiers.

This helps keep readers up to date on the latest advances in our understanding of tumor-host interactions.

The journal publishes short editorials including "position papers," general reviews, original articles, and short communications, providing a forum for the most current experimental and clinical advances in tumor immunology.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science
• Medline
• PubMed
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, Immunology and Microbiology and Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Preservation url
• Apc url
• License

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Biochemistry, Genetics and Molecular Biology, Immunology and Microbiology and Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 3,390.00 EUR. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

  Citation: 1007

  Authors: François, Cedric, Pierre Emmanuel, Sylvain, Stephan, François, Eric, Axel, Laurence, Bruno

• Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

  Citation: 984

  Authors: C. Marcela, Mohamed Labib, Michael I., Elizabeth, David J., Alberto J.

• An immune-active tumor microenvironment favors clinical response to ipilimumab

  Citation: 653

  Authors: Rui-Ru, Scott D., Lisu, Omid, Henrik, John, Suresh, David, Maria, Nathan O., Jeffrey R., Vafa

• Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

  Citation: 556

  Authors: K. L., M. L.

• Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

  Citation: 491

  Authors: Christian, Thomas F., Andreas

• Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

  Citation: 484

  Authors: Christiane, Laurène, Carla M., Petra, Nicole, Loredana, Olivier, Emanuela, Daniel E.

• Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

  Citation: 478

  Authors: Rachel F., Nicola E., Deborah D., Hardev A., Gary W.

• Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

  Citation: 439

  Authors: Suzanne

• Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

  Citation: 424

  Authors: George C., Courtney, Sunil, Laura, Lisa, Richard, Alexander J.

• Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment

  Citation: 401

  Authors: HanByoul, Hye Won, Sang Wun, Sung Hoon, Jae Hoon, Young Tae, Kook